MeSH term
Frequency | Condition_Probility | Cell Survival/drug effects | 2 | 0.0 |
Comparative Study | 56 | 0.0 |
Humans | 225 | 0.0 |
Research Support, Non-U.S. Gov't | 92 | 0.0 |
Adult | 100 | 0.0 |
English Abstract | 44 | 0.0 |
Female | 140 | 0.0 |
Hepatitis B, Chronic/*metabolism | 2 | 66.0 |
Liver/*metabolism | 2 | 0.0 |
Male | 144 | 0.0 |
Human Growth Hormone/*therapeutic use | 2 | 9.0 |
Middle Aged | 95 | 0.0 |
Adolescent | 36 | 0.0 |
Aged | 59 | 0.0 |
Bilirubin/*blood | 3 | 14.0 |
Carcinoma, Hepatocellular/*pathology | 5 | 10.0 |
Albumins/analysis | 7 | 18.0 |
Animals | 44 | 0.0 |
Immunohistochemistry | 3 | 0.0 |
Keratin/analysis | 2 | 0.0 |
Mice | 10 | 0.0 |
Random Allocation | 4 | 0.0 |
Vimentin/analysis | 2 | 0.0 |
alpha-Fetoproteins/analysis | 2 | 0.0 |
Rats | 13 | 0.0 |
Rats, Sprague-Dawley | 3 | 0.0 |
Aged, 80 and over | 11 | 0.0 |
Indicators and Reagents | 2 | 0.0 |
Dialysis Solutions/*chemistry | 3 | 33.0 |
Biological Markers/analysis | 4 | 0.0 |
Cell Count | 2 | 0.0 |
Cross-Sectional Studies | 3 | 0.0 |
Immunoglobulin G/analysis | 2 | 0.0 |
Prognosis | 8 | 0.0 |
Recurrence | 2 | 0.0 |
*Chromosome Mapping | 11 | 0.0 |
Genetic Markers | 9 | 0.0 |
In Situ Hybridization, Fluorescence/methods | 2 | 2.0 |
Polymerase Chain Reaction | 8 | 0.0 |
Alanine Transaminase/blood | 3 | 1.0 |
Bilirubin/blood | 3 | 3.0 |
Blood Proteins/analysis | 6 | 3.0 |
Treatment Outcome | 8 | 0.0 |
*Alleles | 2 | 0.0 |
DNA Primers | 3 | 0.0 |
Lymphocytes | 2 | 1.0 |
Pregnancy | 7 | 0.0 |
Case-Control Studies | 5 | 0.0 |
Infusions, Intravenous | 6 | 0.0 |
Plasma Substitutes/*therapeutic use | 3 | 60.0 |
Prospective Studies | 20 | 0.0 |
Serum Albumin | 3 | 9.0 |
Acute Disease | 2 | 0.0 |
Severity of Illness Index | 4 | 0.0 |
Albumins/metabolism | 4 | 2.0 |
Blood Proteins/metabolism | 5 | 2.0 |
Diagnosis, Differential | 4 | 0.0 |
Models, Biological | 3 | 0.0 |
Serum Albumin/metabolism | 10 | 6.0 |
Blood Proteins/*genetics | 6 | 3.0 |
Gene Frequency | 4 | 0.0 |
*Genetics, Population | 4 | 1.0 |
India | 3 | 0.0 |
Blood Proteins/*analysis | 6 | 4.0 |
Risk Factors | 4 | 0.0 |
Albendazole/*therapeutic use | 2 | 40.0 |
Child | 21 | 0.0 |
Follow-Up Studies | 5 | 0.0 |
Cells, Cultured | 5 | 0.0 |
Biological Markers | 6 | 0.0 |
Child, Preschool | 14 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 25 | 0.0 |
Retrospective Studies | 9 | 0.0 |
Cisplatin/*pharmacology | 2 | 1.0 |
In Vitro | 7 | 0.0 |
Reference Values | 13 | 0.0 |
Tryptophan/*blood | 2 | 22.0 |
Electrophoresis | 2 | 0.0 |
Gestational Age | 4 | 0.0 |
Blood Urea Nitrogen | 4 | 6.0 |
Contrast Media/*adverse effects | 2 | 13.0 |
Creatinine/blood | 5 | 1.0 |
Kidney Function Tests | 3 | 2.0 |
beta 2-Microglobulin/metabolism | 2 | 2.0 |
Age Factors | 5 | 0.0 |
Sex Factors | 2 | 0.0 |
Preoperative Care | 3 | 1.0 |
Albumins/*genetics | 5 | 45.0 |
Serum Albumin/genetics | 3 | 23.0 |
Vitamin D-Binding Protein/*genetics | 5 | 8.0 |
alpha-Fetoproteins/genetics | 4 | 19.0 |
Pedigree | 4 | 0.0 |
Liver Function Tests | 11 | 6.0 |
Plasma Substitutes/*pharmacology | 2 | 25.0 |
Sheep | 2 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Sensitivity and Specificity | 5 | 0.0 |
Sex Characteristics | 2 | 0.0 |
Binding, Competitive | 2 | 0.0 |
Osmolar Concentration | 3 | 0.0 |
Serum Albumin/*metabolism | 4 | 8.0 |
Erythrocyte Transfusion | 2 | 9.0 |
Hemodynamic Processes | 3 | 1.0 |
Hetastarch/*therapeutic use | 2 | 66.0 |
Plasma | 3 | 4.0 |
Infant | 13 | 0.0 |
Liver/*radionuclide imaging | 2 | 33.0 |
Technetium Tc 99m Aggregated Albumin/*diagnostic use | 3 | 25.0 |
Technetium Tc 99m Pentetate/*diagnostic use | 3 | 42.0 |
Demography | 2 | 1.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Base Sequence | 10 | 0.0 |
DNA Probes | 2 | 0.0 |
Species Specificity | 4 | 0.0 |
Exercise/*physiology | 3 | 0.0 |
Regional Blood Flow | 2 | 1.0 |
*Evolution, Molecular | 2 | 0.0 |
Models, Genetic | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 7 | 0.0 |
Time Factors | 12 | 0.0 |
Adsorption | 5 | 3.0 |
Dose-Response Relationship, Drug | 5 | 0.0 |
Regression Analysis | 7 | 0.0 |
Aspartate Aminotransferases/blood | 3 | 2.0 |
Biological Availability | 2 | 0.0 |
Metabolic Clearance Rate | 2 | 0.0 |
Protein Binding | 5 | 0.0 |
Analysis of Variance | 2 | 0.0 |
Drug Therapy, Combination | 4 | 0.0 |
Forced Expiratory Volume/drug effects | 2 | 9.0 |
Blood Glucose/metabolism | 2 | 0.0 |
Transferrin/metabolism | 2 | 1.0 |
Biopsy | 2 | 0.0 |
Chronic Disease | 5 | 0.0 |
Anthropometry | 2 | 0.0 |
*Nutritional Status | 4 | 5.0 |
*Peritoneal Dialysis, Continuous Ambulatory | 3 | 2.0 |
Transferrin/analysis | 4 | 4.0 |
Bronchoalveolar Lavage Fluid/*chemistry | 2 | 3.0 |
Enzyme-Linked Immunosorbent Assay | 6 | 0.0 |
Biological Markers/blood | 4 | 0.0 |
Blood Transfusion | 4 | 2.0 |
Intensive Care Units | 2 | 3.0 |
Longitudinal Studies | 2 | 0.0 |
Proportional Hazards Models | 2 | 0.0 |
Serum Albumin/analysis | 22 | 12.0 |
Survival Analysis | 3 | 0.0 |
Blood Coagulation/*drug effects | 2 | 1.0 |
Thrombelastography | 2 | 18.0 |
Blood Glucose/analysis | 2 | 0.0 |
Infant, Newborn | 5 | 0.0 |
Albumins/genetics | 5 | 21.0 |
*Chromosomes, Human, Pair 4 | 10 | 4.0 |
Polymorphism, Genetic | 3 | 0.0 |
Recombination, Genetic | 2 | 0.0 |
Albuminuria/metabolism | 2 | 20.0 |
Albuminuria/urine | 3 | 15.0 |
Occupational Exposure/*adverse effects | 2 | 2.0 |
Retinol-Binding Proteins/urine | 3 | 33.0 |
Amino Acid Sequence | 5 | 0.0 |
Glycosylation | 2 | 0.0 |
Kinetics | 5 | 0.0 |
Molecular Sequence Data | 11 | 0.0 |
Albuminuria/*urine | 2 | 16.0 |
Cell Differentiation | 2 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
Dioxoles/*pharmacology | 2 | 25.0 |
Genes, p53 | 2 | 0.0 |
Phenotype | 6 | 0.0 |
Cohort Studies | 4 | 0.0 |
Hematocrit | 2 | 0.0 |
Multivariate Analysis | 2 | 0.0 |
Predictive Value of Tests | 5 | 0.0 |
Venezuela | 2 | 6.0 |
Exons | 2 | 0.0 |
Hair Color/*genetics | 2 | 7.0 |
Linkage (Genetics) | 5 | 0.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
Swine/*genetics | 2 | 1.0 |
Blood Loss, Surgical | 2 | 7.0 |
Fluid Therapy | 2 | 9.0 |
Kidney/*drug effects/physiopathology | 3 | 23.0 |
Molecular Weight | 4 | 0.0 |
Osmotic Pressure | 2 | 3.0 |
*Phytotherapy | 3 | 3.0 |
*Nutrition Assessment | 3 | 20.0 |
Prealbumin/*analysis | 5 | 26.0 |
Chromosome Mapping | 3 | 0.0 |
Cholesterol/blood | 3 | 0.0 |
Nutritional Status | 3 | 2.0 |
Fibronectins/*blood | 3 | 11.0 |
Tumor Cells, Cultured | 2 | 0.0 |
Chromatography, Gel | 2 | 0.0 |
Radioimmunoassay | 4 | 0.0 |
Acetylglucosaminidase/urine | 8 | 44.0 |
Alpha-Globulins/urine | 2 | 50.0 |
Immunoglobulin G/urine | 3 | 33.0 |
Platelet Count | 2 | 0.0 |
Liver Neoplasms/*pathology | 4 | 7.0 |
Chromatography, Ion Exchange | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Statistics, Nonparametric | 2 | 0.0 |
Erythrocytes/*enzymology | 2 | 0.0 |
*Genetic Markers | 3 | 0.0 |
*Polymorphism, Genetic | 5 | 0.0 |
Double-Blind Method | 2 | 0.0 |
Injections, Subcutaneous | 3 | 0.0 |
Peak Expiratory Flow Rate/drug effects | 2 | 33.0 |
Evolution | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Acute-Phase Proteins/*analysis | 2 | 2.0 |
Half-Life | 2 | 0.0 |
Cell Line | 6 | 0.0 |
Hamsters | 2 | 0.0 |
Hybrid Cells | 2 | 0.0 |
Biological Markers/urine | 4 | 6.0 |
Collagen Type III/blood | 2 | 50.0 |
Collagen Type IV/blood | 2 | 100.0 |
Hyaluronic Acid/blood | 2 | 28.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Rabbits | 4 | 0.0 |
Forced Expiratory Volume | 2 | 2.0 |
Blotting, Southern | 2 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
Fibrinogen/analysis | 2 | 1.0 |
Blood Protein Electrophoresis | 3 | 2.0 |
Spain/epidemiology | 2 | 1.0 |
Chromatography, High Pressure Liquid | 4 | 0.0 |
*Diagnostic Tests, Routine | 2 | 33.0 |
Creatinine/urine | 2 | 1.0 |
Endothelins/*urine | 2 | 100.0 |
beta 2-Microglobulin/urine | 5 | 22.0 |
Lithotripsy/*adverse effects | 2 | 33.0 |
Lipoprotein(a)/*blood | 2 | 2.0 |
Prealbumin/analysis | 3 | 12.0 |
*Cardiopulmonary Bypass | 2 | 2.0 |
Postoperative Period | 2 | 0.0 |
Immunoenzyme Techniques | 3 | 0.0 |
Crosses, Genetic | 2 | 0.0 |
*Linkage (Genetics) | 3 | 0.0 |
Swine | 2 | 0.0 |
Albuminuria/etiology | 2 | 18.0 |
Glomerular Filtration Rate | 3 | 2.0 |
Kidney/*physiopathology | 2 | 3.0 |
Cadmium/*adverse effects | 2 | 100.0 |
Kidney/*drug effects | 2 | 8.0 |
Albumins/*biosynthesis | 2 | 33.0 |
Carcinoma, Hepatocellular/*metabolism | 2 | 1.0 |
Cell Division | 4 | 0.0 |
Liver Neoplasms/*metabolism | 2 | 2.0 |
alpha-Fetoproteins/*biosynthesis | 2 | 3.0 |
Chromatography, Affinity | 2 | 0.0 |
Permeability | 2 | 1.0 |
Plasma Volume | 2 | 6.0 |
Rats, Inbred Strains | 5 | 0.0 |
Dietary Proteins/administration & dosage | 2 | 5.0 |
Drug Administration Schedule | 2 | 0.0 |
Serum Albumin/*analysis | 5 | 18.0 |
Alleles | 4 | 0.0 |
DNA/genetics | 3 | 0.0 |
Body Weight | 5 | 0.0 |
C-Reactive Protein/metabolism | 2 | 0.0 |
Orosomucoid/metabolism | 2 | 9.0 |
European Continental Ancestry Group/genetics | 3 | 0.0 |
Introns/genetics | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
C-Reactive Protein/analysis | 2 | 0.0 |
Orosomucoid/analysis | 2 | 4.0 |
Creatinine/metabolism | 2 | 2.0 |
Tumor Markers, Biological/blood | 2 | 1.0 |
Protein Biosynthesis | 2 | 0.0 |
Blood Proteins/*metabolism | 2 | 1.0 |
Capillary Permeability | 2 | 2.0 |
Blood Group Antigens/*genetics | 3 | 2.0 |
*Gene Frequency | 5 | 0.0 |
Septicemia/complications | 2 | 33.0 |
Acid-Base Equilibrium | 2 | 8.0 |
*Colloids | 3 | 25.0 |
Pulmonary Edema/etiology | 2 | 33.0 |
Aluminum/*blood | 2 | 66.0 |
Italy | 2 | 0.0 |
Clinical Trials | 2 | 0.0 |
Wounds and Injuries/*complications | 2 | 40.0 |
Albumins/*therapeutic use | 2 | 50.0 |
Colloids | 2 | 8.0 |
Plasma Substitutes | 2 | 50.0 |
Carcinoembryonic Antigen/analysis | 2 | 1.0 |
Mice, Nude | 2 | 0.0 |
Neoplasm Transplantation | 2 | 0.0 |
Orosomucoid/*metabolism | 2 | 18.0 |
Culture Media | 4 | 0.0 |
Transferrin/biosynthesis | 2 | 50.0 |
Blood | 2 | 1.0 |
Histocytochemistry | 3 | 0.0 |
Immunochemistry | 2 | 0.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Serum Albumin/*genetics | 2 | 40.0 |
*Resuscitation | 2 | 40.0 |
Albumins/*administration & dosage | 2 | 50.0 |
Renal Dialysis | 2 | 0.0 |
Erythrocytes/enzymology | 2 | 0.0 |
*Ethnic Groups | 2 | 1.0 |
Aorta, Abdominal/surgery | 2 | 28.0 |
*Osmotic Pressure | 2 | 16.0 |
*Surgical Procedures, Operative | 2 | 6.0 |
Respiratory Function Tests | 2 | 1.0 |
